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Abstract
The aim of this study was to describe the frequency and distribution of Saffold virus in longi-
tudinal stool samples from children, and test for association with development of persistent
autoantibodies predictive of type 1 diabetes. A cohort of Norwegian children carrying the
HLA genotype associated with highest risk of type 1 diabetes (“DR4-DQ8/DR3-DQ2”) was
followed with monthly stool samples from 3 to 35 months of age. Blood samples were tested
for autoantibodies to insulin, glutamic acid decarboxylase65 and Islet Antigen-2. 2077 stool
samples from 27 children with2 repeatedly positive islet autoantibodies (cases), and 53
matched controls were analysed for Saffold virus genomic RNA by semi-quantitative real-
time reverse transcriptase PCR. Saffold virus was found in 53 of 2077 (2.6%) samples, with
similar proportions between cases (2.5%) and controls (2.6%). The probability of being
infected by 3 years of age was 28% (95% CI 0.18–0.40). Viral quantities ranged from <1 to
almost 105 copies/μl. Estimated odds ratio between islet autoimmunity and infection epi-
sodes prior to seroconversion was 1.98 (95% CI: 0.57–6.91, p = 0.29). Saffold virus had no
statistically significant association with islet autoimmunity.
Introduction
Type 1 diabetes is an autoimmune disorder, believed to result from interactions between a sus-
ceptible genetic background and environmental factors. Identification and confirmation of
environmental triggers remains a formidable challenge [1,2].
Several viruses are suspected to be involved in the development of type 1 diabetes, in partic-
ular picornaviruses [3–7]. The genus Cardiovirus (family picornaviridae) includes
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encephalomyocarditis virus (ECMV) and Theilovirus species. Certain strains of EMCV are
highly diabetogenic in mice [8,9], but lack a clear human counterpart [8]. Until recently it was
unclear whether this genus included any human pathogens, although some, such as Theilovirus
Vilyuisk virus [10] have been suspected. The first clear human cardiovirus, Saffold virus
(SAFV), was discovered in 2007 [11]. Subsequently, SAFV has been found in stool [12–19],
respiratory [20,21], sewage [22], cerebrospinal fluid, blood and myocardium samples [15], and
seems to infect young children [23]. The distribution and associated symptoms of SAFV are
still not well described, but SAFV has been reported in both asymptomatic and symptomatic
infections, as is also the case for other human picornaviruses such as enteroviruses and pare-
choviruses [24,25]. Given the associated symptoms and diabetogenic potential of cardioviruses
in rodents, and of related viruses in the picornaviridae family in humans, it is of interest to
study the potential prospective association of SAFV with reported symptoms of disease and
with development of islet autoimmunity and type 1 diabetes.
We aimed to describe the frequency and distribution of SAFV in longitudinal stool samples
from children, and test whether SAFV is associated self-reported symptoms of disease or with
the development of persistent autoantibodies predictive of type 1 diabetes.
Materials and Methods
Subjects and study design
The children included in this study participate in ‘Environmental Triggers of Type 1 Diabetes:
The MIDIA study’, which is described in detail by Stene et al. [26]. Briefly, 46,939 Norwegian
new-borns were screened for the HLA-DQ-DR genotype conferring the highest risk of type 1
diabetes (HLA-DRB104:01-DQA103-DQB103:02/DRB103-DQA105-DQB102), and 911
new-borns carrying this high risk HLA genotype were recruited for further follow up (3 of
these families later withdrew and requested their data to be deleted). A flow-chart of the
recruitment is shown in S1 Fig Blood samples were taken and tested for type 1 diabetes-associ-
ated autoantibodies at 3, 6, 9 and 12 months of age, and every 12 months thereafter. In the case
of an autoantibody positive sample, sampling frequency was increased to every 3–6 months
after 12 months of age. Monthly stool samples were collected between 3 to 35 months of age.
Information on symptoms of infection (coughing and sneezing, diarrhoea, vomiting, or fever)
was recorded in questionnaires at the same ages as the regular blood samples by the parents. At
least one of the parents of children included in the MIDIA study had Norwegian or other Euro-
pean origin (the majority had two Norwegian parents). Written parental consent was obtained.
The study was approved by the Regional Committee for Medical Research Ethics (Office for
Human Research Protections IRB name ‘Regional Med Resch Ethics Comm South IRB #2—
South-East A’, IRB00001871) and the Norwegian Data Protection Authority.
Islet autoantibodies and case-definition. Blood plasma was assayed for autoantibodies
against glutamic acid decarboxylase 65 (GAD), Islet antigen 2 (IA2) or insulin (IAA) as previ-
ously described [26]. The end-point was defined as at least two different autoantibodies in at
least two consecutive blood samples, or one autoantibody and diagnosis of type 1 diabetes. In
this study, 27 children (10 boys and 17 girls) reached the endpoint by 2008, and were assigned
as case children. In subjects who first tested positive for one autoantibody, and then developed
a second autoantibody at a later stage, the time of occurrence of the first autoantibody was
regarded as the first time of positivity. For each case child, two children were randomly selected
from the cohort, matched for duration of follow-up (at least up to the time of endpoint), date
of birth (±1 month, tolerating up to 3 months in a few cases where necessary), and county of
residence. Samples were collected during 2001–2008. Briefly, 80 children were included in the
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analysis (born between 2001 and 2006) with 2077 stool samples tested for SAFV. Detailed char-
acteristics of the study participants are given in Table 1.
Saffold virus assays
The processing and extraction of stool samples is described in detail earlier [27,28]. Briefly, the
samples were received by postal service, diluted and centrifuged. The supernatants were frozen
at -80°C until co-purification of RNA and DNA. To develop and test the PCR method and as
the positive control in the SAFV screening we used plasmids pSAF404 and delPTH5, described
in detail in [29], kindly provided by Drs. Toshiki Himeda and Yoshiro Ohara of Kanazawa
Medical University School of Medicine, Japan. The real-time RT-PCR was tested using a dilu-
tion of plasmid RNA ranging from 10−1 to 106 copies/μl; the RT-PCR consistently detected 1
copy/μl. Plasmid RNA was synthesised by use of the RiboMAX Large Scale RNA Production
Systems (Promega, Madison, WI).
To test for the presence of SAFV, an in-house one-step real-time RT-PCR was developed
targeting the 5´ UTR region of SAFV. Oligonucleotide sequences and their concentrations in
the reactions are given in Table 2. All tests were performed in duplicate using the QuantiTect
Probe RT-PCR Kit (Qiagen, Hilden, Germany) and carried out on an Applied Biosystems 7300
Real Time PCR system (Applied Biosystems, Foster City, CA) with the following thermal
Table 1. Characteristics of the participants in this study.
Case children Control children Total
Number of children 27 53 80
Sex (males/females) 10/17 30/23 40/40
Number of other children in the household 0 5 16 21
1 9 27 36
2 13 10 23
First degree relatives with type 1 diabetes 10/27 3/53 13/80
Median age (range) at last stool samplea 30.2 (9.1–35.8) 35.0 (12.5–37.5) 33.0 (9.1–37.5)
Median age (range) of ﬁrst autoantibody-positive samplea 12.1 (5.9–37.4) - -
Median age (range)a, b 42.4 (9.2–83.8) 38.8 (12.4–84.3)
a in months
b at the time when all the 27 cases were ascertained by the end of 2008.
doi:10.1371/journal.pone.0136849.t001
Table 2. Primers and Probes used in the Study.
Sequence 5´-3´ Positiona Concentration
SAFV-detectionb
SAFV_692F ATGCCGGAAACGGTGAAGA 662 300 nM
SAFV_827R ACCGCTCACAGCAGTGGATC 817 900 nM
SAFV_743P_MGBc FAM-TCGAAACAGCTGTAGCGAC 713 150 nM
SAFV genotyping
SAFV_VP1_FC AYAATGCTGARAAAGGMAARG 2977 500 nM
SAFV_VP1_RG CCRGGAATTTCATATTGRCA 3904 500 nM
a position given when aligning to NCBI Reference Sequence: NC_009448.2
b F: forward primer; R: reverse primer; P: Probe.
c Minor Groove Binder.
doi:10.1371/journal.pone.0136849.t002
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profile: 30 minutes at 50°C, 15 minutes at 95°C followed by 45 cycles of 15 seconds at 94°C and
1 minute at 60°C. To quantify the amounts of virus present a standard curve ranging from 100
to 105 copies/μl was run alongside the samples, using 2μl of plasmid RNA as template. The
viral quantity was set to the mean quantity of the duplicates. No cross-reactivity with human
entero- and human parechoviruses was indicated in the PCR by testing several samples known
to be positive for these viruses.
To get information on SAFV genotypes, a PCR targeting the VP1 region was performed on
the positive samples using primers described in Table 2. The PCR product was sequenced
using standard Sanger sequencing on an ABI 3730 DNA Analyzer (Applied Biosystems, Foster
City, CA). A complete protocol is available from the authors upon request.
Data analysis
A detailed description of analysis methods is given in the S1 File. Briefly, the association of
SAFV with islet autoimmunity (and other variables) was primarily analysed using a mixed
effects logistic regression model with SAFV infections as the dependent variable. The primary
analysis involved only samples collected up to islet autoimmunity for the cases and the corre-
sponding age in the matched controls, but pre-planned sub-group analyses included other time
widows such as samples collected to the date of the last autoantibody negative blood sample.
To adjust for potential confounders, variables such as sex, first degree relatives with type 1 dia-
betes, number of siblings in the household and breastfeeding were added as independent vari-
ables to the model, excluding missing observations. A midpoint rooted phylogenetic tree was
constructed using the obtained VP1 sequences together with other sequences from GenBank.
The robustness of the estimated phylogenetic three was determined by bootstrapping with
1000 replicates.
Results
SAFV positive stool samples by sex, age and season
The total proportion of SAFV positive samples was 53 of 2077 samples (2.6%). There was no
statistically significant difference in the proportion of SAFV positive samples between the sexes
(1.65% males, 3.44% females). Overall there were 28 infection episodes (defined as a positive
sample, followed by any number of consecutive positive samples) during follow-up.
SAFV positivity was elevated around 12–28 months of age with a peak at 18–21 months fol-
lowed by an apparent drop (S2 Fig), although the association with age was not significant
(p = 0.1). The proportions of positive samples were highest during the winter months (S3 Fig),
but this observation was not statistically significant.
Patterns of SAFV infection in individuals during follow-up
Of the 80 children followed, 19 (24%) tested positive for SAFV at least once. The probability of
having a SAFV-positive stool sample before 2 years of age was 18% (95% CI 11–29) (Fig 1).
Thirteen children had multiple positive samples, with the maximum being seven positive sam-
ples in each of two children. Infections often started with a high quantity that dropped over
time (S4 Fig). The infection episodes lasted from 1 to 4 consecutive monthly samples, with a
median infection length of 2 months for the first SAFV infection. Viral quantities ranged from
less than one to 96417 copies/μl, with a median of 164 copies/μl (S1 Table).
Saffold Virus and Islet Autoimmunity
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Saffold virus and symptoms of infectious disease
Run separately, symptoms of the common cold, diarrhoea or fever were not significantly asso-
ciated with the presence of SAFV RNA in faeces (results not shown). However, when including
all of these symptoms as independent variables in the model, there was a tendency for SAFV
positive samples to occur at the same time as symptoms of the common cold were reported by
the parents (uncorrected OR 2.43, 95% CI 1.00–5.90, p = 0.051). Diarrhoea or fever remained
not significantly associated with the presence of SAFV RNA in faeces. Due to missing observa-
tion only 1479, 1629 and 1561 were included in the analysis of common cold, diarrhoea or
fever respectively. In the combined model 1371 observations were included in the analysis.
Saffold virus and with type 1 diabetes- associated islet autoimmunity
The observed frequency of SAFV infections was slightly higher among case children than
among matched control children, but the difference was not statistically significant (Table 3).
Adjusting for sex, number of siblings in the household, breastfeeding or first degree relatives
with type 1 diabetes did not have a major impact on the conclusions (data not shown). Due to
missing observations only 1911 observations were included in the adjusted analysis.
Conditional logistic regression analysis gave similar results (odds ratio for1 vs 0 infec-
tions: 2.25, 95% CI: 0.53–9.63, p = 0.27). There was no significant difference after restriction to
specific predefined time periods prior to the appearance of autoantibodies (S2 Table), nor
when only using samples taken before and concurrent with the last autoantibody negative
blood sample. Using infections occurring together with reported symptoms, infections lasting
2 months or positive samples in lieu of infection episodes in the analysis gave similar results
Fig 1. Probability of having the first infection with Saffold virus during follow-up. Probability is calculated as 1 minus the Kaplan-Meier estimate. 2A: All
children (solid line), case children (dotted line) and control children (dashed line). 2B: All children (solid line) with 95% confidence interval bands. There is no
statistical difference between the case and control children.
doi:10.1371/journal.pone.0136849.g001
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(data not shown). Neither were there any significant differences between case children and
control children in the viral quantities (median 174 vs. 164 for cases and controls, respectively)
or length of infection (median 1.5 vs. 1 for all SAFV infections in case and control children,
respectively).
We also tested whether our results were influenced by the choice of positivity threshold, but
the lack of significant association remained also after increasing this to 10, 1000 or 10000 cop-
ies/μl in the statistical analysis (data not shown). Finally, we ran the analysis using only infec-
tions prior to 6 months of age, and prior to 12 months of age, again with no significant results
(data not shown).
Sequencing results
Partial VP1 sequences were obtained from 23 of the 53 positive samples. In general, samples
with low viral quantities were unsuccessful. There was 16 SAFV-2 and 7 SAFV-3 positive sam-
ples; other genotypes were not found in our study. Two children were infected with both geno-
types at different times (S4 Fig), and re-infection with the same genotype at a later time was
also observed.
A phylogenetic tree of the sequences, and their geographical distribution, is presented in Fig
2. Generally, the strains observed clustered together in regards to geography and time period,
showing that different strains were circulating at different times/locations in Norway. The clus-
ters should not be taken as local outbreaks, as the areas with most positive samples are areas of
high population density in Norway, which contribute most of the participants in the cohort.
Discussion
In this first large-scale, longitudinal study of SAFV and type 1 diabetes-associated islet autoim-
munity, we did not find any significant association. We further described the frequency of
SAFV by age, season and infectious symptoms in one of the largest, longitudinal study of other-
wise healthy children published to date.
We are only aware of a single previous study that attempted to investigate the relation
between SAFV and islet autoimmunity [30], but with only 49 stool samples assayed and none
observed to be SAFV-positive, that study was clearly underpowered. Similar to our study the
participants had a high genetic risk of type 1 diabetes, and the results can not necessarily be
generalised to the general population. However our results will be relevant for a major fraction
of future type 1 diabetes cases [31]. While seroepidemiological studies suggest that SAFV is
ubiquitous [23,32], we observed infections in about a quarter of our children during follow-up
and the proportion of SAFV-positive stool samples was relatively low. Among more than 2000
stool samples tested in our study, 2.6% were positive, which seems to be in line with most other
available studies of SAFV occurrence [12–14,16,17,33]. This is considerably lower than what
Table 3. Saffold virus infection episodes in the case and control children.
Case children (%) Control children (%) OR, 95% CI
Whole observation period 10/644 (1.55%) 18/1433(1.26%) 1.27, 0.58–2.78
After IA 5/284 (1.76%) 13/724 (1.80%) 1.06, 0.36–3.08
Before IA 5/360 (1.39%) 5/709 (0.71%) 1.98, 0.57–6.91
The number of infection episodes and total samples, with the percent in parentheses, and the results from
the mixed effects logistic regression are given for case and control children at different time periods. IA:
islet autoimmunity; OR: Odds Ratio; 95% CI: 95% Conﬁdence Interval.
doi:10.1371/journal.pone.0136849.t003
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we have previously found for enterovirus and parechovirus in the same samples [6,27]. This
relatively low frequency of SAFV positivity suggest that extremely large scale studies are neces-
sary to rule out possible associations of modest to small magnitude of SAFV with islet autoim-
munity, type 1 diabetes or symptoms of infections. Although it is possible that diabetogenic
SAFV strains exist, similar to the EMCV-D strain in mice [8,9], these would be expected to be
the cause of a relatively small proportion of type 1 diabetes cases.
Most available studies of SAFV occurrence based on PCR detection were conducted on
patients with symptoms of infectious disease, and included only one or a few samples from
each subject during a limited time period. Few previous publications have reported SAFV
occurrence in population based studies. A recent Danish study found 2.8% of stools to be posi-
tive, consistent with our observation [14]. In another recent Finnish study, SAFV was tested in
160 stool and nasal swab samples collected at the time of infectious disease symptoms from 45
children, resulting in only one SAFV positive stool sample [18]. Other smaller studies of
Fig 2. Infections and GenBank sequences in relation to Norwegian municipalities. Phylogenetic tree of the Saffold virus genotypes and geographical
distribution of sequenced samples. Strains from the current study are colored blue. Sequences are denoted with GenBank accesion number, then the
country of origin and year of sampling in parentheses. The tree is rooted by using midpoint rooting Scale bars represent 0.1 nucleotide substitutions per site.
Only one sequence per infection episode is presented in the phylogenetic tree as the dominating sequence seemed stable and there were no evident
mutations in the VP1 sequence during an infection (results not shown), supporting the assumption that consecutive positive samples were part of the same
infectious episode.
doi:10.1371/journal.pone.0136849.g002
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symptomatic children have reported from 1.1% to 3.2% positive samples [12,13,16,17,33],
whereas a study of German children reported 7.8% positive stool samples [12] and two studies
of Pakistani and Afghani children reported ~10% positive stool samples [19,34]. Some random
variation is to be expected with the small number of observed positive samples and total sam-
ples in these studies, and there is also variation in age and clinical characteristics which make
direct comparisons difficult. While there may be many other factors influencing the frequency
of SAFV infection, it seems at current that there are no large differences in observed frequency
between studies of symptomatic children and population based studies, which is also consistent
with the lack of association with common infectious disease symptoms (fever, diarrhoea, vom-
iting or common cold symptoms) in our study. It is worth noting that SAFV have been found
in invasive infections [15]. It seems likely that SAFV may act similarly to other picornaviruses
with generally asymptomatic infections that may cause various serious conditions in a small
fraction of cases.
We observed some variation by age and season, and although this was not statistically sig-
nificant, we would expect that the true frequency of SAFV varies to some extent with these var-
iables. When comparing SAFV frequency among studies, we therefore believe that both age
and season are important to consider, but perhaps most importantly the frequency and dura-
tion of longitudinal sample collection. The fact that we observed on average two consecutive
positive monthly stool samples suggests that monthly samples should be sufficient to detect
most infections, although we cannot rule out the possibility that infections with faecal shedding
for less than a month were missed.
Detection of SAFV in stool samples with PCR methods should be highly sensitive, but it is
important to consider the sensitivity of the PCR and the specificity of the primers. For instance,
the previously mentioned studies that report higher proportion of positive samples used nested
PCR, targeting the 2C region of SAFV [34] and 5-UTR [12,19], while ours and others men-
tioned targeted the 5’UTR and did not use nested PCR. Of necessity, PCR primers can only be
designed based on the currently known SAFV sequences. While we do not expect this to be a
major problem because the 5’ UTR tend to be well conserved, we cannot rule out the possibility
that there are other SAFV with sequences for which our primers have limited sensitivity.
While there seems to be geographical differences in the proportion of SAFV positive sam-
ples when comparing the studies from Germany [12], Pakistan and Afghanistan[19,34] to
those from Denmark[14] and the current study from Norway, these differences could be due to
the methods used (nested vs. non-nested PCR), or due to the fact that the studies from Ger-
many, Pakistan and Afghanistan included older children (12 and15 years of age, respec-
tively) while the Scandinavian studies are in younger children (3 years of age). It is worth
noting that seroepidemiological results are similar in several countries (Netherlands, Finland,
Cameroon, Indonesia), with>75% having antibodies against SAFV by 24 months of age
[23,32]. This speaks against geographical or socioeconomic differences in frequency of SAFV
infections in young children. The apparent discrepancy between the SAFV-frequency in PCR
based studies as ours and seroepidemiological studies may be due to a variety of factors. On
one hand, short duration and infrequent sampling of stool samples used for PCR testing might
lead to underreporting. On the other hand, cross-reactivity and limited specificity of the anti-
body assays, or SAFV infections outside the gut, might be the reason for the higher reported
cumulative incidence in seroepidemiological studies.
The SAFV genotypes found in this study (SAFV-2 and -3) seem to be the more commonly
reported strains also in other studies [12,14,16]. Our findings are similar to what was found
during similar time periods in the Netherlands [32] and in Denmark [14], indicating that these
genotypes are the most commonly found in Western Europe. Unfortunately, the number of
Saffold Virus and Islet Autoimmunity
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samples positive for each specific SAFV genotype was too low for any meaningful interpreta-
tion of associations with age, season, symptoms or islet autoimmunity in our study.
Conclusions
In this first large-scale study of SAFV and islet autoimmunity, we found 2.6% positives among
more than 2000 monthly stool samples from children at genetic risk of type 1 diabetes who
were followed from 3 months of age. While we observed a slightly higher frequency among
those who later developed islet autoimmunity, the association was not significant. We found
no significant associations between SAFV infections and reported symptoms of infection,
which should be kept in mind when evaluating a positive finding in stool. Based on our obser-
vations, we can conclude that extremely large studies are necessary to exclude potential associa-
tions of modest magnitude, particularly if investigating specific SAFV genotypes.
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